| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1022: Bevacizumab gamma for treating wet age-related macular degeneration |
|
Medicine details |
|
| Medicine name | bevacizumab gamma (Lytenava®) |
| Formulation | intravitreal injection |
| Reference number | 5363 |
| Indication | For treating wet age-related macular degeneration |
| Company | Outlook Therapeutics |
| BNF chapter | Eye |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/10/2024 |
| NICE guidance | TA1022: Bevacizumab gamma for treating wet age-related macular degeneration |